Description du projet
Faire progresser la recherche sur la thérapie génique et cellulaire en République tchèque
Les médicaments de thérapie innovante (advanced therapy medicinal products, ATMP) sont des thérapies et des traitements de pointe qui utilisent des technologies et des techniques novatrices pour traiter des maladies complexes. Les ATMP comprennent les thérapies géniques et régénératives, ainsi que les options de médecine personnalisée, qui ciblent généralement les maladies rares héréditaires. Financé par le programme HORIZON, le projet CREATIC vise à établir un centre de thérapie avancée et d’immunothérapie en République tchèque. Cette installation phare se concentrera sur les médicaments antimicrobiens qui s’appuient sur les découvertes récentes dans les domaines de la génomique, de la biologie cellulaire et de l’édition de gènes. Le centre collaborera avec des institutions de recherche européennes de premier plan, ce qui élargira sa capacité de recherche et d’innovation dans le domaine des thérapies géniques et cellulaires, et lui permettra de s’aligner sur la vision de l’Europe en matière de traitements individualisés pour les maladies rares.
Objectif
Progress in biomedical science enables scientists to use a whole new toolbox to treat significant groups of diseases, such as inherited rare diseases or diverse rare cancers. Advanced therapy medicinal products (ATMPs) apply recent advances in genomics, cell biology and/or gene editing to deliver truly personalized curative options. The project proposes to establish flagship ATMP-focused facility on the margin of academia and clinics: Central European Advanced Therapy and Immunotherapy Centre (CREATIC) at the Masaryk University (MU) in Brno, Czech Republic. MU will team up with the leading European research institutions: (1) Fraunhofer Institute for Cell Therapy and Immunology IZI, (2) Leipzig University, which together forms a significant cluster of research excellence in research, development and training in the fields of gene and cell therapies and (3) Copenhagen University with unique expertise in biomedical innovation law, intellectual property, biomedical ethics, privacy and regulatory framework, and health technology assessment. Combining STM and SSH disciplines the project will allow for (i) fundamental expansion of the scope of the R&I activities of all partners to build multidisciplinary excellence facilitating the delivery of ATMPs to patients who need them; (ii) establishment of the high level of decision-making autonomy for the CREATIC, which will allow significant organizational and management changes creating spirit and conditions for cutting-edge research and innovation in the Centre, and (iii) strengthen the smart specialization of the Czech Republic (RIS3 CZ 2021-2027) in the domain of Advanced medicine and drugs through the involvement of actors from the academic, public, private and societal sector. Our approach reflects research priorities and societal challenges outlined in the Pharmaceutical Strategy for Europe, which proposes ‘bedside’ manufacture of highly individualised medicines as a future trend in treating rare diseases with ATMPs.
Champ scientifique
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesclinical medicineoncology
- medical and health sciencesbasic medicineimmunologyimmunotherapy
- medical and health sciencesmedical biotechnologycells technologies
Mots‑clés
Programme(s)
Régime de financement
HORIZON-CSA - HORIZON Coordination and Support ActionsCoordinateur
601 77 Brno
Tchéquie